Clinical Trials Logo

Clinical Trial Summary

This study is part of a series of projects to improve protection against meningitis. Previously, researchers have given nose drops containing N. lactamica to over 400 volunteers and shown that many of them become colonised with N. lactamica without causing any illness or disease. This has previously been shown to prevent people from becoming colonised with N. meningitidis which can cause meningitis. This study aims to give nose drops containing N. lactamica to healthy adults in Mali, to see if they become safely colonised. In the future the study team would like to find out how N.lactamica helps children resist N.meningitidis, and develop new vaccines that exploit that mechanism.


Clinical Trial Description

In this pilot research, the study team will use a methodology of nasal inoculation with reconstituted lyophilised N. lactamica (hereafter LyoNlac) developed in a previous, UK-based, human challenge study. This methodology and will be developed further and validated in healthy Malian adults. A dose-ranging strategy will be used, starting with the dose identified as the standard inoculum in healthy adults in the UK, which was the dose required to induce colonisation in approximately 80% of volunteers. The dose will be escalated to a dose able to induce a similar level of colonisation in Malian adults. This study will inform the study team whether intranasal inoculation of reconstituted lyophilised Nlac (hereafter, lyoNlac), can result in immunising colonisation of adult Malian volunteers and the optimal dose to achieve this. This dose and methodology will then be used in future studies looking at the duration and immunogenicity of colonisation induced by LyoNlac in Mali. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04665791
Study type Interventional
Source Center for Vaccine Development - Mali
Contact Diane F Gbesemete, BM MRCPCH
Phone +44 2381204956
Email d.gbesemete@soton.ac.uk
Status Recruiting
Phase N/A
Start date March 2, 2021
Completion date January 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04689191 - A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine Phase 3
Recruiting NCT04689165 - A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine Phase 3
Completed NCT00780806 - Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults Phase 1/Phase 2
Completed NCT03378258 - Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.
Completed NCT03205371 - Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers Phase 3
Completed NCT01352793 - A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years Phase 3
Not yet recruiting NCT06113198 - A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age Phase 4
Completed NCT03295318 - Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds Phase 2
Completed NCT03493919 - A Sourcing Study to Collect Human Blood Samples From Healthy Adults Phase 4
Completed NCT00474526 - A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants Phase 3
Completed NCT00297687 - Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults Phase 1
Withdrawn NCT03431675 - Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018 Phase 4
Recruiting NCT02878291 - Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months Phase 1
Completed NCT00314041 - Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants Phase 2
Recruiting NCT04685850 - Long-term Sequelae of Childhood Meningitis and Meningococcal Purpura Fulminans
Completed NCT03587207 - Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years Phase 2
Completed NCT03824093 - High and Low Resource Interventions to Promote HPV Vaccines N/A
Completed NCT04707391 - Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine Phase 3
Terminated NCT00798304 - Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants Phase 2
Recruiting NCT03682939 - Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population Phase 4